BFC Planning’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
Other funds holding GLUE
BFC Planning's GLUE Position: Q3 2026 in Review
BFC Planning held its Monte Rosa Therapeutics (GLUE) position steady in Q3 2026 at 16 shares worth $191. The position accounts for ﹤0.01% of the portfolio, ranked #3357.
BFC Planning first reported a position in GLUE in Q2 2026 and has held it in 2 quarters since. The position peaked at $387 in Q2 2026. 124 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.
- BFC Planning held 16 shares of Monte Rosa Therapeutics worth $191 as of Q3 2026.
- BFC Planning left its Monte Rosa Therapeutics share count unchanged in Q3 2026.
- Monte Rosa Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3357 holding.
- BFC Planning first reported a position in Monte Rosa Therapeutics in Q2 2026 and has held it in 2 quarters since.
- BFC Planning's Monte Rosa Therapeutics position peaked at $387 in Q2 2026.
- 124 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.